elironrasib
elironrasib: sourced relationships with 1 company · 4 clinical trials tracked.
elironrasib evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
How could elironrasib → RVMD affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence7 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| REVOLUTION MEDICINES, INC. (RVMD) Advanced Solid Tumors; Non-Small Cell Lung Cancer (NSCLC) | Phase 3 |
Clinical Trial Registry Records (4)
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors
Primary endpoint: Number of patients with adverse events (AEs)
A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
Primary endpoint: Adverse events
Phase 1b/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients With Advanced KRAS G12C-Mutated Solid Tumors
Primary endpoint: Number of patients with adverse events (AEs) in Phase 1b
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Primary endpoint: Adverse events
Frequently asked questions
Which companies have sourced relationships with elironrasib?
elironrasib has dated SEC/FDA relationship records for REVOLUTION MEDICINES, INC..
How many clinical trials involve elironrasib?
BioSniper tracks 4 clinical trials involving elironrasib.